Zentiharvest Biotech: Announcement of Board Approval for Q1 2026 Consolidated Financial Report

1. Date of submission to or resolution by the board of directors: 2026/05/05 2. Date of approval by the audit committee: 2026/05/05 3. Reporting period for financial report or annual self-reported financial information (XXX/XX/XX~XXX/XX/XX): 2026/01/01~2026/03/31 4. Operating revenue accumulated from January 1 to the end of this period (in thousands of NTD): 869,503 5. Operating gross profit (gross loss) accumulated from January 1 to the end of this period (in thousands of NTD): 749,396 6. Operating income (loss) accumulated from January 1 to the end of this period (in thousands of NTD): 518,169 7. Net profit (net loss) before tax accumulated from January 1 to the end of this period (in thousands of NTD): 532,246 8. Net profit (net loss) for this period accumulated from January 1 to the end of this period (in thousands of NTD): 426,698 9. Net profit (loss) attributable to owners of the parent company accumulated from January 1 to the end of this period (in thousands of NTD): 426,698 10. Basic earnings (loss) per share accumulated from January 1 to the end of this period (in NTD): 4.15 11. Total assets at the end of the period (in thousands of NTD): 4,067,795 12. Total liabilities at the end of the period (in thousands of NTD): 1,391,161 13. Equity attributable to owners of the parent company at the end of the period (in thousands of NTD): 2,676,634 14. Other matters to be specified: None Keyword: Material Information